COVID-19

COVID-19 vaccines: under evaluation

The European Medicines Agency (EMA) is evaluating potential COVID-19 vaccines to enable the distribution of promising vaccines in the European Union (EU) as soon as possible. 

COVID-19 vaccines under rolling review

EMA's Committee for Medicinal Products for Human Use (CHMP) is evaluating the following COVID-19 vaccines:

VaccineVaccine developerKey milestonesMore information
CVnCoVCureVac AG
Start of rolling review: 12/02/2021
NVX-CoV2373
Novavax CZ AS
Start of rolling review: 03/02/2021
Sputnik V (Gam-COVID-Vac)Russia’s Gamaleya National Centre of Epidemiology and MicrobiologyStart of rolling review: 04/03/2021EMA starts rolling review of the Sputnik V COVID-19 vaccine

For more information on the expedited evaluation procedure EMA is applying for COVID-19 vaccines, including the rolling review, see:

COVID-19 vaccines under conditional marketing authorisation evaluation

There are no marketing authorisation applications currently under evaluation by EMA’s CHMP.

For more information on the expedited evaluation procedure EMA is applying for COVID-19 vaccines, including the conditional marketing authorisation, see:

Topics

How useful was this page?

Add your rating
Average
10 ratings
7 ratings
2 ratings
4 ratings
16 ratings